MDxHealth (MDXH) Projected to Post Quarterly Earnings on Thursday

MDxHealth (NASDAQ:MDXH) is expected to issue its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $26.0540 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

MDxHealth Stock Up 4.8%

NASDAQ:MDXH opened at $3.68 on Thursday. The firm has a market cap of $174.03 million, a PE ratio of -5.75 and a beta of 1.64. MDxHealth has a 12 month low of $1.35 and a 12 month high of $5.33. The company’s 50-day moving average price is $3.50 and its two-hundred day moving average price is $3.72.

Hedge Funds Weigh In On MDxHealth

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MDXH. Intesa Sanpaolo Wealth Management bought a new stake in shares of MDxHealth in the 4th quarter valued at about $36,000. Lido Advisors LLC bought a new stake in shares of MDxHealth in the 3rd quarter valued at $48,000. Jefferies Financial Group Inc. bought a new stake in shares of MDxHealth in the 3rd quarter valued at $53,000. Squarepoint Ops LLC acquired a new stake in MDxHealth during the 4th quarter worth $51,000. Finally, Bank of America Corp DE lifted its holdings in MDxHealth by 5,164.0% during the third quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after acquiring an additional 14,769 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. TD Cowen increased their price target on MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of MDxHealth in a research note on Tuesday, December 23rd. Finally, Lake Street Capital boosted their target price on MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.75.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.